Teva Pharmaceuticals
TEVA
449 hedge funds and large institutions have $5.53B invested in Teva Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 63 funds opening new positions, 128 increasing their positions, 156 reducing their positions, and 52 closing their positions.
21% more first-time investments, than exits
New positions opened: 63 | Existing positions closed: 52
9% more capital invested
Capital invested by funds: $5.06B → $5.53B (+$470M)
1% more funds holding
Funds holding: 443 → 449 (+6)
0.89% more ownership
Funds ownership: 51.36% → 52.25% (+0.89%)
18% less repeat investments, than reductions
Existing positions increased: 128 | Existing positions reduced: 156
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
29% less call options, than puts
Call options by funds: $211M | Put options by funds: $298M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
+$29.9M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$23.5M |
| 3 |
MIFH
Migdal Insurance & Financial Holdings
Petach Tikva,
Israel
|
+$22.1M |
| 4 |
MMH
Menora Mivtachim Holdings
Ramat Gan,
Israel
|
+$17.5M |
| 5 |
Grantham, Mayo, Van Otterloo & Co (GMO)
Boston,
Massachusetts
|
+$17.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$24.6M |
| 2 |
PF
Phoenix Financial
Givatayim,
Israel
|
-$24.2M |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$13.8M |
| 4 |
National Pension Service
Jeonju-Si, Jeollabuk-Do,
South Korea
|
-$13.6M |
| 5 |
JP Morgan Chase
New York
|
-$13.5M |
TEVA Hedge Fund Activity: Q4 2020 in Review
449 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Teva Pharmaceuticals (TEVA) for Q4 2020, worth a combined $5.53B — up 9.3% from $5.06B a quarter earlier.
Buyers outnumbered sellers: 63 funds opened new TEVA positions and 52 closed out — a net gain of 11 holders — while 128 added to existing stakes and 156 trimmed.
The largest buyer was Capital International Investors, adding an estimated $29.9M. The largest seller was Arrowstreet Capital, cutting an estimated $24.6M.
- 449 institutional investors held Teva Pharmaceuticals (TEVA) as of Q4 2020, up from 443 in Q3 2020.
- Funds reported $5.53B of Teva Pharmaceuticals stock for Q4 2020, up 9.3% quarter-over-quarter.
- 63 funds opened new Teva Pharmaceuticals positions in Q4 2020 and 52 closed out, a net change of +11 holders.
- The largest Teva Pharmaceuticals buyer in Q4 2020 was Capital International Investors, an estimated $29.9M added.
- The largest Teva Pharmaceuticals seller in Q4 2020 was Arrowstreet Capital, an estimated $24.6M sold.
Based on aggregated 13F filings for Q4 2020.